CN1162152C - 糖尿病治疗剂 - Google Patents
糖尿病治疗剂 Download PDFInfo
- Publication number
- CN1162152C CN1162152C CNB018000959A CN01800095A CN1162152C CN 1162152 C CN1162152 C CN 1162152C CN B018000959 A CNB018000959 A CN B018000959A CN 01800095 A CN01800095 A CN 01800095A CN 1162152 C CN1162152 C CN 1162152C
- Authority
- CN
- China
- Prior art keywords
- cyanoimino
- thiazolidin
- benzal
- diabetes
- remedies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/70—Sulfur atoms
- C07D277/74—Sulfur atoms substituted by carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Description
化合物 | 给药量 | 血糖低下率 |
化合物No.1 | 75mg/kg | 31% |
150mg/kg | 37% | |
化合物No.3 | 75mg/kg | 24% |
150mg/kg | 49% | |
化合物No.22 | 75mg/kg | 16% |
150mg/kg | 34% | |
化合物No.63 | 75mg/kg | 32% |
特洛列酮 | 150mg/kg | 18% |
化合物 | 吸光度比 | 化合物 | 吸光度比 |
化合物No.1化合物No.2化合物No.3化合物No.4化合物No.5化合物No.7化合物No.8化合物No.10化合物No.12化合物No.13 | 1.461.571.482.621.871.931.952.121.742.15 | 化合物No.16化合物No.19化合物No.21化合物No.22化合物No.26化合物No.34化合物No.42化合物No.44化合物No.45化合物No.47 | 1.181.512.021.731.091.402.011.831.141.24 |
对照 | 1.00 |
化合物 | β-脂蛋白降低率 | 游离脂肪酸降低率 | 甘油三酯降低率 |
化合物No.1化合物No.3化合物No.13化合物No.21化合物No.22 | 51%65%65%38%56% | 39%58%38%25%41% | 69%85%70%41%65% |
化合物 | 甘油三酯降低率(%) | 化合物 | 甘油三酯降低率(%) |
化合物No.1 | 47 | 化合物No.20 | 54 |
化合物No.2 | 67 | 化合物No.21 | 48 |
化合物No.3 | 64 | 化合物No.22 | 65 |
化合物No.4 | 42 | 化合物No.26 | 46 |
化合物No.6 | 84 | 化合物No.28 | 36 |
化合物No.7 | 60 | 化合物No.32 | 47 |
化合物No.8 | 47 | 化合物No.34 | 71 |
化合物No.9 | 49 | 化合物No.37 | 41 |
化合物No.10 | 39 | 化合物No.39 | 57 |
化合物No.11 | 62 | 化合物No.40 | 42 |
化合物No.12 | 59 | 化合物No.43 | 67 |
化合物No.13 | 55 | 化合物No.45 | 43 |
化合物No.14 | 36 | 化合物No.47 | 69 |
化合物No.15 | 47 | 化合物No.49 | 39 |
化合物No.16 | 54 | 化合物No.51 | 67 |
化合物No.17 | 37 | 化合物No.52 | 44 |
化合物No.19 | 38 |
化合物 | 总胆甾醇降低率(%) | 甘油三酯降低率(%) |
化合物No.2化合物No.3化合物No.7化合物No.9化合物No.14化合物No.15 | 271618151132 | 571712152461 |
Claims (18)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP14970/00 | 2000-01-24 | ||
JP2000014970A JP2001199888A (ja) | 2000-01-24 | 2000-01-24 | 糖尿病治療剤 |
JP14970/2000 | 2000-01-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1358096A CN1358096A (zh) | 2002-07-10 |
CN1162152C true CN1162152C (zh) | 2004-08-18 |
Family
ID=18542342
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB018000959A Expired - Fee Related CN1162152C (zh) | 2000-01-24 | 2001-01-22 | 糖尿病治疗剂 |
Country Status (12)
Country | Link |
---|---|
US (1) | US6667328B2 (zh) |
EP (1) | EP1179343B1 (zh) |
JP (1) | JP2001199888A (zh) |
KR (1) | KR100682696B1 (zh) |
CN (1) | CN1162152C (zh) |
AT (1) | ATE273706T1 (zh) |
AU (1) | AU780597B2 (zh) |
CA (1) | CA2365085C (zh) |
DE (1) | DE60104949D1 (zh) |
HK (1) | HK1045121A1 (zh) |
IL (1) | IL145336A (zh) |
WO (1) | WO2001052849A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1316548A4 (en) | 2000-07-05 | 2004-05-19 | Ajinomoto Kk | ACYLSULFONAMIDE DERIVATIVES |
US6794401B2 (en) * | 2003-01-17 | 2004-09-21 | Bexel Pharmaceuticals, Inc. | Amino acid phenoxy ethers |
US7521465B2 (en) * | 2003-01-17 | 2009-04-21 | Bexel Pharmaceuticals, Inc. | Diphenyl ether derivatives |
US7781464B2 (en) * | 2003-01-17 | 2010-08-24 | Bexel Pharmaceuticals, Inc. | Heterocyclic diphenyl ethers |
US7087576B2 (en) * | 2003-10-07 | 2006-08-08 | Bexel Pharmaceuticals, Inc. | Dipeptide phenyl ethers |
US9830423B2 (en) * | 2013-03-13 | 2017-11-28 | Abhishek Biswas | Virtual communication platform for healthcare |
US11694797B2 (en) | 2012-10-30 | 2023-07-04 | Neil S. Davey | Virtual healthcare communication platform |
WO2015160772A1 (en) * | 2014-04-15 | 2015-10-22 | Janssen Pharmaceutica Nv | Tetrahydro-benzoimidazolyl modulators of tgr5 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989008651A1 (en) * | 1988-03-08 | 1989-09-21 | Pfizer Inc. | Hypoglycemic thiazolidinedione derivatives |
US5143929A (en) * | 1991-05-09 | 1992-09-01 | Warner-Lambert Company | 2-substituted thiazolidinone, oxazolidinone, and imidazolidinone derivatives of fenamates as antiinflammatory agents |
JPH07165371A (ja) * | 1993-10-06 | 1995-06-27 | Japan Tobacco Inc | テープ巻き付け方法および装置 |
JPH0892249A (ja) * | 1994-07-20 | 1996-04-09 | Sankyo Co Ltd | スルホンアミド誘導体 |
JP3871354B2 (ja) * | 1994-07-29 | 2007-01-24 | 株式会社フジモト・コーポレーション | 新規な2−(n−シアノイミノ)チアゾリジン−4−オン誘導体 |
JPH08157461A (ja) * | 1994-12-07 | 1996-06-18 | Sankyo Co Ltd | スルホン誘導体 |
JPH09165371A (ja) | 1995-10-09 | 1997-06-24 | Sankyo Co Ltd | 複素環化合物を含有する医薬 |
JP3884096B2 (ja) * | 1995-10-13 | 2007-02-21 | 株式会社フジモト・コーポレーション | 新規な2−(n−シアノイミノ)チアゾリジン−4−オン誘導体 |
JP2000026438A (ja) * | 1998-07-14 | 2000-01-25 | Fujimoto Brothers:Kk | 新規な2−(n−シアノイミノ)チアゾリジン−4− オン誘導体 |
US6380229B1 (en) * | 1999-11-12 | 2002-04-30 | Fujimoto Co., Ltd. | 2-(N-cyanoimino)thiazolidin-4-one derivatives |
-
2000
- 2000-01-24 JP JP2000014970A patent/JP2001199888A/ja active Pending
-
2001
- 2001-01-22 US US09/914,921 patent/US6667328B2/en not_active Expired - Fee Related
- 2001-01-22 AT AT01942552T patent/ATE273706T1/de not_active IP Right Cessation
- 2001-01-22 CN CNB018000959A patent/CN1162152C/zh not_active Expired - Fee Related
- 2001-01-22 KR KR1020017012136A patent/KR100682696B1/ko not_active IP Right Cessation
- 2001-01-22 EP EP01942552A patent/EP1179343B1/en not_active Expired - Lifetime
- 2001-01-22 DE DE60104949T patent/DE60104949D1/de not_active Expired - Lifetime
- 2001-01-22 CA CA2365085A patent/CA2365085C/en not_active Expired - Fee Related
- 2001-01-22 IL IL145336A patent/IL145336A/en not_active IP Right Cessation
- 2001-01-22 AU AU57906/01A patent/AU780597B2/en not_active Ceased
- 2001-01-22 WO PCT/JP2001/000398 patent/WO2001052849A1/ja active IP Right Grant
-
2002
- 2002-09-17 HK HK02106791A patent/HK1045121A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
IL145336A0 (en) | 2002-06-30 |
CA2365085C (en) | 2011-01-04 |
AU780597B2 (en) | 2005-04-07 |
ATE273706T1 (de) | 2004-09-15 |
EP1179343A4 (en) | 2003-05-07 |
CN1358096A (zh) | 2002-07-10 |
IL145336A (en) | 2006-10-31 |
HK1045121A1 (en) | 2002-11-15 |
WO2001052849A1 (fr) | 2001-07-26 |
KR100682696B1 (ko) | 2007-02-15 |
CA2365085A1 (en) | 2001-07-26 |
US6667328B2 (en) | 2003-12-23 |
JP2001199888A (ja) | 2001-07-24 |
KR20010108387A (ko) | 2001-12-07 |
DE60104949D1 (de) | 2004-09-23 |
US20030078193A1 (en) | 2003-04-24 |
AU5790601A (en) | 2001-07-31 |
EP1179343A1 (en) | 2002-02-13 |
EP1179343B1 (en) | 2004-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2216513T3 (es) | Nuevos analogos heterociclicos de compuestos de difeniletileno. | |
CN1106195C (zh) | 噻唑烷二酮衍生物及相关的抗高血糖药物在治疗患有非胰岛素依赖性糖尿病危险病症中的应用 | |
DE69916881T2 (de) | Antihypertriglyceridemische, antihyperglykemische, antiangiogene und wundheilende substituierte indolalkansäure | |
CN1248683C (zh) | 二肽基肽酶iv抑制剂在制备治疗2型糖尿病的药物中的用途 | |
CN1070863C (zh) | 膦酸二酯衍生物 | |
CN1040324C (zh) | 新的噻唑烷二酮及含有这些化合物的药剂 | |
CN101679365A (zh) | 作为葡萄糖激酶激活剂的新型吡咯-2-甲酰胺衍生物、它们的制造方法和药学应用 | |
CN1148492A (zh) | 动脉硬化和黄瘤的治疗 | |
CN1162152C (zh) | 糖尿病治疗剂 | |
CN1159305C (zh) | 新的2-(n-氰基亚氨基)噻唑烷-4-酮衍生物 | |
CN1170575A (zh) | 胰腺炎的治疗及预防 | |
DE60130031T2 (de) | Dihydronaphthalinderivat verbindungen und arzneimittel, die diese verbindungen als wirkstoff enthalten | |
CN1633421A (zh) | HPPAR-α受体的噁唑/噻唑衍生物活化剂 | |
CA2108064C (fr) | Nouveaux composes de thiazolidine dione, leur procede de preparation et les compositions pharmaceutiques les contenant | |
CN1946712A (zh) | 吡咯烷衍生物 | |
CN1192683A (zh) | 减少非胰岛素依赖型糖尿病患者外源性胰岛素给药量的方法 | |
EP3027605B1 (en) | Novel indazole compounds and a process for the preparation thereof | |
CN1268395C (zh) | 慢性肾脏疾病治疗药物 | |
RU2005141516A (ru) | Производные анилина | |
US20040192688A1 (en) | Alpha-substituted naphthyloxy omega-substituted alkyl/aryl amino-substituted alkane derivatives as agent for treatment or prophylaxis of diabetes and related metabolic disorders | |
CN1524854A (zh) | 一种噻唑烷二酮的衍生物及其药用制剂的制备方法和应用 | |
CN1163105A (zh) | 骨质疏松的治疗和予防 | |
CN1834091A (zh) | 用于治疗糖尿病和肥胖症的取代的甘氨酸衍生物 | |
CN101547902A (zh) | 治疗与胰岛素抵抗或高血糖症相关的代谢障碍的吡啶衍生化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1045121 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: FUJIMOTO PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: TOMOYISHI MOTOPULAZEZ CORP. Effective date: 20101028 Owner name: FUJIMOTO CO., LTD. Free format text: FORMER OWNER: FUJIMOTO PHARMACEUTICAL CO., LTD. Effective date: 20101028 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20101028 Address after: Japan Osaka Patentee after: FUJIMOTO Co.,Ltd. Address before: Japan Osaka Patentee before: FUJIMOTO PHARMACEUTICAL Corp. Effective date of registration: 20101028 Address after: Japan Osaka Patentee after: FUJIMOTO PHARMACEUTICAL Corp. Address before: Japan Osaka Patentee before: Fujimoto Brothers Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040818 Termination date: 20150122 |
|
EXPY | Termination of patent right or utility model |